Filgrastim biosimilar is under clinical development by Biosimilar Solutions and currently in Phase I for Chemotherapy Induced Neutropenia. According to GlobalData, Phase I drugs for Chemotherapy Induced Neutropenia have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Filgrastim biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Filgrastim biosimilar overview

filgrastim biosimilar (BSC-1020) is under development for the treatment of severe chronic neutropenia, febrile neutropenia and chemotherapy induced neutropenia. It is administered through subcutaneous route. The drug candidate acts by targeting granulocyte colony-stimulating factor (G-CSF) receptor.

Biosimilar Solutions overview

Biosimilar Solutions (Biosimilar) is a company that provide biologic medicines to improve the life of patients. The company is headquartered in United States.

For a complete picture of Filgrastim biosimilar’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.